拉贝洛尔联合酚妥拉明对妊娠期高血压患者的疗效题录

目的探讨拉贝洛尔联合酚妥拉明对妊娠期高血压患者妊娠结局及爱帕琳肽(Apelin)、血栓调节蛋白(PTM)水平的影响。方法本研究为随机对照试验。选择2019年2月至2022年2月临沂市人民医院收治的86例妊娠期高血压患者为研究对象, 以随机数字表法分为观察组(43例)与对照组(43例)。对照组年龄(29.12±3.93)岁, 孕周(29.63±4.12)周;观察组年龄(28.23±3.19)岁, 孕周(31.01±4.13)周。对照组采用酚妥拉明治疗, 观察组在对照组的基础上给予拉贝洛尔治疗, 两组均持续治疗7 d后观察效果。对比两组患者的临床疗效及不良妊娠结局, 比较治疗前后Apelin、PTM水平。统计学方法采用χ2检验、独立样本t检验、配对t检验。结果观察组患者的临床总有效率高于对照组93.02%(40/43)比76.74%(33/43)], 两组比较差异有统计学意义(χ2=4.440, P=0.035)。治疗前, 两组患者的Apelin、PTM水平比较差异均无统计学意义(均P>0.05);治疗后, 两组的Apelin、PTM均降低, 且观察组患者的Apelin、PTM水平...

Effect of labetalol combined with phentolamine on patients with gestational hypertension

Objective　To investigate the effects of labetalol combined with phentolamine on the pregnancy outcomes and levels of Apelin and thrombomodulin (PTM) in patients with gestational hypertension. Methods　It was a randomized controlled trial. A total of 86 patients with gestational hypertension admitted to Linyi People's Hospital from February 2019 to February 2022 were selected as the research objects. They were divided into an observation group (43 cases) and a control group (43 cases) by the random number table method. The age of the control group was (29.12±3.93) years old and the gestational age was (29.63±4.12) weeks; the age of the observation group was (28.23±3.19) years old and the gestational age was (31.01±4.13) weeks. The control group was treated with phentolamine, and the observation group was treated with labetalol on the basis of the control group. The effects of both groups were observed after 7 days of continuous treatment. The clinical effects and adverse pregnancy outcomes of the two groups were compared, and the levels of Apelin and PTM before and after treatment were compared. χ² test, independent sample t test, and paired t test were used. Results　The clinical effective rate of the observation group was higher than that of the control group 93.02% (40/43) vs. 76.74% (33/43)], with a statistically significant difference between the two groups (χ²=4.440, P=0.035). Before treatment, there were no statistically significant differences in the levels of Apelin and PTM between the two groups (both P>0.05). After treatment, the levels of Apelin and PTM decreased in both groups, and the levels of Apelin and PTM in the observation group were lower than those in the control group (38.52±5.12) ng/L vs. (43.25±6.25) ng/L, (201.32±18.25) ng/L vs. (281.51±19.25) ng/L], with statistically significant differences (t=3.839 and 19.824; both P<0.001). The incidence of adverse pregnancy outcomes in the observation group was lower than that in the control group 4.65% (2/43) vs. 20.93% (9/45)] (χ²=5.108, P=0.024). Conclusion　Labetalol combined with phentolamine can improve the therapeutic effect in patients with gestational hypertension, reduce the levels of Apelin and PTM, and reduce the incidence of adverse pregnancy outcomes.